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ABSTRACT 
INCREASING HPV VACCINATION RATES USING  
SOCIAL MARKETING STRATEGIES 
 
by Sharon Wilson Catledge 
December 2014   
The human papillomavirus (HPV) is the most common sexually-transmitted 
infection (STI).  Approximately 20 million Americans between the ages of 15 and 49 
years currently have HPV with > 6.2 million new HPV infections estimated to occur each 
year.  Yet, HPV vaccination rates remain relatively low.  More than 40 strains of HPV 
are transmitted through genital contact during vaginal, anal, or oral sex and can infect 
males and females.  In addition to causing genital warts, HPV is associated with cervical, 
vulvar, vaginal, anus, penile, and oropharyngeal cancers.  In women, the most prominent 
type of cancer is cervical with > 12,000 diagnoses each year and 4,000 expected to die.  
In Mississippi, a total of 1,829 HPV-associated cancers were diagnosed between 2004 
and 2008, with an average of 33,369 cases in the United States (Centers for Disease 
Control and Prevention [CDC], 2012a).  In 2000, the estimated cost of management of 
HPV for individuals between the age of 15 and 24 years totaled $2.9 billion.  The aim of 
this study was to increase vaccination rates using social marketing strategies.  The study 
was guided by an integrative approach using education sessions and pretest/posttest 
design to evaluate knowledge of HPV.  Research data were obtained from 25 participants 
between the ages of 18 and 20 years.  According to the CDC (2012c), males and females 
between the ages of 9 and 26 years should be offered the Gardasil® vaccine to achieve 
 iii 
disease prevention.  Research findings revealed increasing knowledge about HPV caused 
an increase in the number of students that received the vaccine after the intervention.  
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CHAPTER I 
 
INTRODUCTION 
Problem Statement 
According to the Centers for Disease Control and Prevention (CDC, 2012a), 
human papillomavirus (HPV) is the most common sexually-transmitted infection (STI).  
Approximately 20 million Americans between the ages of 15 and 49 currently have HPV 
with more than 6.2 million new HPV infections estimated to occur each year.  Yet, HPV 
vaccination rates remain relatively low (Cermak, Cottrell, & Murnan, 2010; Cox, 2006; 
Mahoney, 2006; Ylitalo, Lee, & Mehta, 2013).  In the United States 70% of cervical 
cancers and 90% of genital warts are caused by the most common HPV types 6, 11, 16, 
and 18 (Mississippi State Department of Health [MSDH], 2011).  The HPV vaccine 
protects against most of the common strains (CDC, 2012b; MSDH, 2011).  Currently, 
two vaccines protect against HPV; however, only Gardasil® (quadrivalent vaccine) is 
recommended for males and females and protects against cervical cancer, vulvar cancer, 
vaginal cancer, anal cancer, and genital warts (Mahoney, 2006).  The CDC (2012a) 
recommends initiating the vaccine between the ages of 11 and 12 years but may be given 
as early as 9 years of age.  Additionally, catch-up vaccines are recommended for those 
between the ages of 13 and 26 years who did not have all three doses when they were 
younger (CDC, 2012a).  There is no cure for HPV infection, but some of the problems it 
causes are treatable.  In 2000, medical costs for the treatment of HPV for ages 15 to 24 
years were estimated at $2.9 billion, putting HPV ahead of other STIs, such as genital 
herpes, chlamydia, and gonorrhea.  Males and females between the ages of 9 and 26 years 
should be offered the Gardasil® vaccine to achieve disease prevention (Ylitalo et al., 
2013).   
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The purpose of this capstone project was to increase the HPV vaccination rates of 
students between the ages of 18 and 20 years on The University of Southern Mississippi 
(USM) Hattiesburg Campus through the use of social marketing strategies.  For this 
project, social marketing strategies included education and active promotion of the HPV 
vaccine to change healthcare outcomes by raising awareness and increasing the actual 
number of HPV vaccines administered at the USM Health Clinic.  Education and 
recommendations are critical for the students if the vaccine rates are to increase. 
Needs Assessment 
Of the 16,000 students enrolled at USM, 13,652 are undergraduates and 2,819 are 
graduate students.  The project director, who works at the USM Health Clinic, offers 
services to entering freshmen through graduate school between the ages of 16 years and  
60+ years.  The 3-dose HPV vaccine is available at the clinic.  The vaccine costs 
approximately $140 for each dose and is covered by most insurance plans.  For the 
uninsured, the clinic partners with Merck™ in the patient assistance program for 
payment.  During the last 3 years there were 62,698 patient visits to the USM Health 
Clinic.  Care was provided to > 16,000 male students and > 33,000 female students.  
However, only about 200 doses of the HPV vaccine were given during that 3-year period.  
A chart audit was conducted to verify how many of the students had the HPV vaccine.  A 
random sample of 200 charts was reviewed (n = 150 females and n = 50 males), and 5 
females were found to have had the HPV vaccine. 
The clinical staff at USM Health Clinic consists of 3 providers (2 doctors and 1 
nurse practitioner) and 5 nurses.  During an interview conducted by the project director 
earlier this year, all 3 providers reported they are aware of HPV, support the HPV 
vaccine, but seldom recommend the vaccine.  Additionally, the providers reported that if 
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they discuss HPV, then they recommend the vaccine.  All of the nurses reported they are 
aware of the vaccine, support the vaccine, but never discuss the vaccine.  
Background and Significance 
According to the CDC (2013c), “79 million Americans have HPV with 
approximately 14 million new infections each year” (p. 1).  HPV infection can result in 
cancer of the cervix, other female genital cancers, penile cancer, and anal cancers 
(MSDH, 2011).  Cervical cancer, the second most common cancer in women, claims the 
lives of > 300,000 worldwide each year.  In the United States, > 10,000 women are 
diagnosed with cervical cancer each year with > 3,000 women expected to die each year 
(MSDH, 2011; Ratanasiripong, Cheng, & Enriquez, 2013).  As part of Healthy People 
2020’s 10-year objectives for improving the nation’s health, there is an initiative to 
increase cervical cancer screenings and reduce the number of HPV infections.  Persistent 
HPV infection is implicated in 70% to 90 % of cervical cancers and 80% of penile 
cancers (MSDH, 2011; Ratanasiripong et al., 2013).  Men who have sex with men have a 
higher incidence of anal cancer, and most of them are linked to HPV (MSDH, 2011).  
“Vaccinating males, especially before the age of sexual activity, helps protect both men 
and women from disease” (MSDH, 2011, p. 1).  Oral cancers account for > 20,000 
Americans each year, and HPV is indicated in nearly one fourth of those affected (CDC, 
2012a).  
HPV is a papillomavirus that invades human epithelial cells and manifests in 
mucosal membranes throughout the body (American Cancer Society [ACS], 2014).  The 
most common membranes where the virus is found are the throat, mouth, feet, fingers, 
nails, anus, and cervix (ACS, 2014).  Many strains of HPV can affect the genital area and 
are classified as either high-risk or low-risk (CDC, 2012a).  “Both low-risk and high-risk 
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strains can cause the growth of abnormal cells, but generally only high-risk type lead to 
cancer” (Cermak et al., 2010, pp. 229-230).  Most known strains of HPV cause no 
symptoms; however, some can cause condylomata (genital warts) while others can 
develop into cancer (ACS, 2014).  Types 16, 18, 33, 35, 45, 51, 52, 56, 58, 59, 68, 73, 
and 82 can cause cancer (CDC, 2012a).  Strains 16 and 18 are considered high-risk and 
most commonly associated with cervical, vulvar, vaginal, anus, and penile cancer; 
whereas, HPV 6 and 11 are low-risk types associated with genital warts and some low-
grade cervical cell abnormalities (CDC, 2012; Cermak et al., 2010; Cox, 2006; Pollack, 
Balkin, Edouard, Cutts, & Broutet, 2007). 
There are no signs or symptoms of HPV until warts appear or changes are seen in 
genital tissue.  In 90% of the cases, the body’s immune system will clear HPV naturally 
within 1 to 2 years; therefore, most individuals infected with HPV do not develop 
symptoms or health problems (CDC, 2012a).  However, individuals with high-risk HPV 
that does not clear up are at greatest risk for cancer (Cox, 2006).  Male and females are at 
risk for HPV with the first sexual encounter with an average age of 14 years for first 
intercourse (French & Dishion, 2003).    
There are no urine tests or blood tests that would specifically assess for HPV.  
The only available test is a cervical smear examination performed on females using the 
Pap test (American Congress of Obstetricians and Gynecologists [ACOG], 2012).  Yet, 
according to the ACOG (2012) guidelines, the use of the Pap test is recommended for 
females after the age of 21 years.  The U.S. Preventive Services Task Force, the 
American Cancer Society, and the American Society for Colposcopy and Cervical 
Pathology do not recommend pap test for females under the age of 21 years regardless of 
sexual history (ACOG, 2012).  HPV screening in combination with the Pap test is not 
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recommended before age 30 years due to risk versus benefit analyses, indicating that the 
harm outweighs the benefits (ACOG, 2012).  Unfortunately, there is no test for males. 
Once detected, there is no treatment for the HPV, but there are treatments for the 
problems caused by the virus (CDC, 2012c).  The body’s immune system can fight off 
HPV naturally within 1 to 2 years (CDC, 2012c).  However, not all infections are cleared 
and eventually may manifest most commonly as genital warts and/or cancer.  The genital 
warts may form in the vulva, vagina, cervix, urethra, penis, scrotum, anus, and under the 
foreskin of an uncircumcised penis (CDC, 2011).  Providers can treat genital warts with 
the use of cryotherapy, electrocauterization, or laser therapy; and topical solutions can be 
used for home treatment (CDC, 2011).  In some cases, they are treated with injections of 
interferon, a medication that boosts the immune system response and suppresses cell 
proliferation (CDC, 2011).   
Genital warts can cause physical symptoms (e.g., pain, bleeding, and itching) as 
well as psychological symptoms (embarrassment and poor self-image) and serves as a 
constant reminder of an STI (CDC, 2011).  Treating warts does not insure the virus is 
gone, and the warts may reappear.  Even if the warts are not visible, it is important to 
note that the virus can still spread (CDC, 2011, Cox, 2006; Planned Parenthood, 2013).  
Without treatment, visible genital warts can be self-limiting, remain unchanged, or 
multiply in size or in number (CDC, 2011).  Therefore, the aim of treatment is for 
cosmetic purposes to remove growths and reduce the virus by stimulating the immune 
response to help control the infection.  Removing the warts can be painful and may 
require multiple treatments (CDC, 2011).   
Understanding HPV and HPV-related illness and the stress that it can cause is 
important.  “The emotional toll of dealing with HPV is often as difficult as the medical 
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management of the disease” (National Cervical Cancer Coalition [NCCC], 2013, p. 1).  
The diagnosis of HPV, cost of treatment, and the stigma of having a STI can lead to 
stress.  Additionally, anxiety is associated with a positive cancer screening, discomfort 
from additional diagnostic and treatment procedures, bleeding from treatment, and an 
increased risk of pregnancy complications (ACOG, 2012).  Removing the warts can be 
painful and may require multiple treatments, which further add to the stress (Cox, 2006).  
Although the body can rid itself of the virus, if genital warts develop, most individuals 
prefer to have the warts treated immediately (Cox, 2006).  
If high-risk HPV is detected during the Pap test, the female is then referred to a 
provider who can further evaluate the cervical changes.  Most often a colposcopy (using a 
special magnifying device to look at the vulva, vagina, and cervix) is recommended to 
view the problem area more clearly.  The vagina and cervix may be swabbed with 
vinegar (acetic acid) and sometimes iodine (Lugol's solution) to see problem areas more 
clearly.  If dysplasia is found with the colposcopy, additional treatment, such as 
cryotherapy, laser, loop electrocautery excision procedure (LEEP), or a cone biopsy, may 
be indicated.  Specimens obtained with the LEEP and cone biopsy procedures are 
assessed microscopically to be sure the abnormal cells are not cancerous (National 
Cancer Institute [NCI], 2010).  
In Mississippi, from 2004-2008, there were 1,829 HPV-associated cancers 
diagnosed with an average of 33,369 cases in the United States (CDC, 2012b).  Financial 
constraints should be taken into consideration when looking for ways to improve 
vaccination rates (Pourat & Jones, 2012).  Medical management of HPV costs billions of 
dollars, putting the treatment above the cost of other STIs (CDC, 2012c).   
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With the lack of tests for males and curative options for both male and females, 
the best treatment for HPV is prevention.  Gardasil® is the only quadrivalent HPV 
vaccine licensed for use among females and males between the ages of 9 and 26 years for 
prevention of vaccine HPV-type related cancers (CDC, 2012a).  The vaccine is 
administered by intramuscular injection, and the recommended schedule is a 3-dose 
series with the second and third doses administered 2 and 6 months after the first dose.  
Catch-up vaccines are recommended for males and females between the ages of 13 and 
26 years who have not completed the 3-dose series (CDC, 2012a; Marchand, Glenn, & 
Bastani, 2012; Ylitalo et al., 2013).   
Review of Relevant Literature 
A comprehensive literature search was conducted using databases and Internet 
searches.  The databases consisted of Medline, CINAHL, EPCOHOST, PUB MED, and 
Bio Med Central.  Internet sites used were Centers for Disease Control and Prevention 
and Mississippi State Department of Health.  A review of 165 articles and 20 abstracts 
was conducted with 26 articles included in this literature summary, which assisted with 
focus of increasing HPV vaccine rates.  Keywords used for search were human 
papillomavirus, HPV in females, HPV in males, HPV vaccinations, HPV between the 
ages of 17 and 20 years, HPV in college students, and combinations of keywords.  
Excluded were articles addressing HPV in pediatrics, adolescents, parental consent, and 
cancer. 
The summary of the literature will address HPV, HPV-related cancers, and the 
relationship of the HPV vaccine to HPV.  The findings were limited to HPV related to 
females, males, and college students, provider recommendation, lack of uptake of the 
vaccine, and barriers and benefits of the HPV vaccine.  The review of literature will be 
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divided into three sections: (a) knowledge of HPV, (b) effects of HPV, and (c) provider 
recommendation of the HPV vaccine.   
Knowledge of HPV 
HPV is transmitted through genital contact during vaginal or anal sex although it 
can be transmitted during oral sex and genital-to-genital contact (CDC, 2012a; Cox, 
2006).  According to Cox (2006), the higher the number of sex partners within 2 years of 
initiating sexual intercourse, the higher the chance of contracting HPV.  At least half of 
all sexually active men and women get genital HPV at some time in their lives (CDC, 
2012a).  
In 2006, the Food and Drug Administration (FDA) licensed the HPV vaccine and 
the Advisory Committee on Immunization Practices (ACIP) recommended HPV 
vaccination for girls between the ages of 11 and 12 years but can be started at the age of 9 
years.  In 2009, vaccination recommendations for boys were published (CDC, 2012a).  
After risk and benefit analyses, the HPV vaccination was approved to prevent HPV and 
its associated diseases, such as cervical cancer, vaginal cancer, vulvar cancer, anal 
cancer, and genital warts (CDC, 2012c; Marchand et al., 2012; Saraiya, Rosser, & 
Cooper, 2012; Ylitalo et al., 2013).  Although the recommended ages are 11 to 12 years, 
the CDC states the vaccine can be given through the age of 26 years.  For those who do 
not receive the HPV vaccine between the ages of 9 and 11 years or do not complete the 3-
dose series, catch-up vaccines are recommended for ages 13 to 26 years (CDC, 2012b; 
Marchand et al., 2012; Ylitalo et al., 2013).  Two vaccines are approved to aid in 
protecting against HPV.  However, only Gardasil® (quadrivalent vaccine) is 
recommended for both males and females and protects against cervical cancer, vulvar 
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cancer, vaginal cancer, anal cancer, and genital warts (Mahoney, 2006; Rubin, Kuttab, 
Rihani, & Reutzel, 2012; Tomljenovic & Shaw, 2012).   
Since 2006, the quadrivalent HPV vaccine has been studied extensively for safety 
and efficacy (Pomfret, Gagnon, & Gilchrist, 2010).  In a systematic review of evidence, 
Pomfret et al. (2010) concluded that the quadrivalent vaccine was well tolerated and 
effective in the management of HPV, thus preventing precancerous lesions.  Disease 
prevention was evident by numerous clinical trials that included over 21,000 females 
between the ages of 9 and 26 years (Pomfret et al., 2010).  The review revealed > 23 
million doses of the quadrivalent vaccine had been given in the United States through 
December 2008.  Of the reported adverse events through the Vaccine Adverse Event 
Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical 
Immunization Safety Assessment (CISA), 94% were considered non-serious and 6% 
were viewed as serious (Pomfret et al., 2010).  After evaluation of the report, the CDC 
then concluded there was no link between the vaccine and the serious events (Pomfret et 
al., 2010). 
Effects of HPV 
Most people infected are asymptomatic (CDC, 2012b).  More than 40 strains of 
HPV can infect the genitals of males and females (CDC, 2012a; Cermak et al., 2010; 
Cox, 2006).  The high-risk HPV strains 16 and 18 are most commonly associated with 
genital cancers (Cermak et al., 2010; Cox, 2006; Pollack et al., 2007).  In contrast, HPV 6 
and 11 are associated with genital warts and some low-grade cervical cell abnormalities 
and are considered low-risk (Cox, 2006; Pollack et al., 2007).  In Mississippi from 2004-
2008, there were 1,829 HPV associated cancers with an average of 33,369 cases in the 
United States (CDC, 2012b).  In the United States, about 12,000 women get cervical 
10 
 
 
 
cancer every year, and about 4,000 are expected to die from it (CDC, 2012a).  The costs 
of treating HPV and related diseases are estimated at or above $4 billion annually (Pourat 
& Jones, 2012).  
HPV is as common in the male as it is in the female, although rarely causing 
significant health problems.  Men with HPV can develop genital warts and penile cancer; 
for men who have sex with men, HPV can lead to anal cancer (CDC, 2012c).  College-
age males are considered a high-risk population for STIs because of their sexual 
promiscuity, unsafe sex habits, lack of concern, lack of knowledge, and perceived risks 
(Katz, Krieger, & Roberto, 2011).  Katz and colleagues astutely made the connection 
that, “vaccinating males will indirectly assist with preventing HPV-related diseases (e.g. 
cervical cancer) in females” (p. 176). 
Although most individuals never know they have HPV, about 10% to 13% will 
progress to a high-grade lesion, and about 70% to 91% will regress within 2 years (Cox, 
2006).  In women, cervical cancer is the second leading cause of cancer with > 12,000 
diagnoses each year in the United States and 4,000 expected to die (CDC, 2012; Cermak 
et al., 2010; Cox, 2006; Pollack et al., 2007).  The incidence of anal cancer has been on 
the rise since the 1970s, and HPV is implicated in most anal cancers and about 80% of 
penile cancers (Cox, 2006).  Oropharyngeal and oral cancers occur in > 20,000 
Americans each year, and HPV is indicated in nearly 25% of those affected (Cox, 2006).   
The annual medical costs of HPV in 2000 for ages 15 to 24 years were estimated 
at $2.9 billion, putting HPV ahead of the costs of other STIs, such as genital herpes, 
chlamydia, and gonorrhea (Mahoney, 2006).  Management of abnormal Pap tests is the 
driver for a large portion of the $2.9 billion costs (Cox, 2006; Mahoney, 2006).  In 
addition to the $2.9 billion, the costs of treating cervical cancer and increased needs for 
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screening bring an added financial burden to health care with costs reportedly at $2.3 
billion annually (Cox, 2006).   
Pourat and Jones (2012) identified lack of knowledge and financial costs as 
barriers to receiving the HPV vaccine.  “Understanding the impact of financial barriers on 
adherence to HPV vaccination is needed to improve HPV vaccination rates and to 
prevent HPV infection and its disease” (Pourat & Jones, 2012, p. 323).  Each Gardasil® 
injection costs approximately $140, resulting in a total of $420 for the three injections 
(CDC, 2012a; Pourat & Jones, 2012).  The Gardasil® vaccines can be financed by private 
insurance, Medicaid for those under the age of 18 years, and Federal programs such as 
Vaccines for Children (VFC) to assist the uninsured (CDC, 2012a).  Moreover, there are 
patient assistance programs to assist with the cost.  
Negative connotations can be associated with an HPV diagnosis.  These 
connotations include anxiety, unnecessary cancer screenings which cause discomfort and 
increased risk for future complications, and the shame of having an STI (ACOG, 2012).   
Provider Recommendation of HPV Vaccine 
Healthy People 2020 (2013) reported 16.6% of females received the HPV vaccine 
in 2008, and their objective was to increase the coverage to 80% by 2020.  Despite the 
growing epidemic, < 50% of adolescents receive the HPV vaccine (Ylitalo et al., 2013).  
An explanation for the low number receiving the HPV vaccine may be attributed to a lack 
of recommendations from the healthcare providers (Ylitalo et al., 2013).  According to 
the researchers, healthcare professionals’ failure to recommend the vaccine is among the 
leading barriers concerning the HPV vaccinations.  The researchers reported that 
adolescent females are five times as likely to receive the HPV vaccine with a provider’s 
recommendation (Ylitalo et al., 2013).  Research reveals that the prevalence of provider 
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recommendation for HPV vaccine is low, which suggests that healthcare providers are 
missing patient education opportunities.  Increasing HPV vaccination rates hinges on 
healthcare providers and other healthcare professionals recommending both the vaccine 
and educating patients (Moon, 2013).  According to Moon (2013), healthcare providers 
are not recommending the HPV vaccine.  However, if the vaccine rates are to increase, it 
is imperative that the providers use each patient encounter to educate and recommend the 
HPV vaccine.  Historically, if healthcare providers promote a product with a strong 
endorsement, patients are more likely to accept it.  Addressing issues regarding vaccine 
safety, adverse effects, and appropriate age for vaccination in a clear concise manner may 
be a way healthcare providers can reduce concerns and misconceptions about the vaccine 
(Moon, 2013).  Strategies to increase HPV vaccination rates include educating healthcare 
professionals and the general public about the importance of vaccinating adolescent 
males, females, and ensuring that underserved populations are informed about and given 
access to the vaccine (Moon, 2013). 
Theoretical Framework 
Social marketing is a well-defined marketing discipline and served as the 
framework for this capstone project as a basis to increase HPV vaccination rates on the 
Hattiesburg Campus of USM for students between the ages of 18 and 20 years.  Social 
marketing is a process that uses marketing principles and techniques to promote a target 
audience to voluntarily accept, reject, modify, or abandon behaviors that will benefit the 
individuals, groups, or society (Lee & Kotler, 2011).  The process follows 10 steps: (a) 
identifying the problems, (b) obtaining a detailed description of the situation, (c) 
reviewing strengths and weaknesses in the environment, (d) identifying target audience, 
(e) establishing objectives and goals, (f) identifying benefits and competition, (g) creating 
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a firm position, (h) developing marketing strategies, (i) developing a plan for monitoring, 
and (j) reporting outcomes. 
 The Social Marketing Process 
 Step 1.  The background history of HPV is discussed under the background 
significance and literature review.  Based on the needs assessment, the problem identified 
was a lack of HPV vaccinations.  The campaign focus of the social marketing strategy 
was to increase the HPV vaccination rates on the Hattiesburg Campus of USM.   
 Step 2.  SWOT (strengths, weaknesses, opportunities, and threats) analysis was 
used to identify the present situation within the campus for strengths, weaknesses, 
opportunities, and threats of the environment.  The purpose of SWOT analysis is to 
gather, evaluate, and analyze information to determine key issues of an organization and 
facilitate a strategic approach.  Strengths for implementing the project were as follows: 
(a) resources, (b) key stakeholders who support the project, (c) easy accessibility of the 
vaccine, and (d) a potential grant opportunity with MerckTM.  Weaknesses for the project 
included the following: (a) cost of vaccine, (b) series of injections, and (c) overcoming 
barriers to vaccine.  Opportunities included (a) increasing knowledge of HPV and HPV 
vaccine, (b) increasing the rates of HPV vaccines, (c) decreasing the number of HPV- 
related cancers, (d) decreasing the genital warts, (e) decreasing the medical costs for 
treatment of HPV and HPV-related illness, and (f) the potential to impact policy.  Threats 
were (a) perceived barriers, (b) vaccine not mandatory, and (c) personal feelings 
regarding injections. 
 Step 3.  The three steps to identify target audiences included segmenting the 
market, using established criteria to evaluate the segments, and choosing one or more of 
the segments to target.  According to the CDC (2012a), 20 million Americans have HPV 
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and millions of others are expected to get it during their lifetime.  According to the 
current author’s research, the number receiving the HPV vaccine remains relatively low.  
The quadrivalent vaccine is recommended for males and females as early as age 9 years, 
and catch-up vaccines can be given through the age of 26 years.  Sexually-transmitted 
infections are very prevalent on the campus of USM.  The target audience for the social 
marketing campaign was students between the ages of 17 and 20 years on the USM 
Hattiesburg Campus.  Identifying key stakeholders was crucial in implementing a 
successful project.  The stakeholders associated with the social marketing project to 
increase HPV vaccine included the Doctor of Nursing Practice student, medical director 
of the clinic, and other providers, such as nurses in the clinic, pharmacists, 
administration, Merck patient assistance representatives, and private insurance carriers.    
 Step 4.  The social marketing component of step 4 included the objectives that 
identify the behaviors which needed to be changed, knowledge level that was needed, and 
the belief that nurse practitioners needed to make the necessary change.  According to 
Lee and Kotler (2011), behavior, knowledge, and belief are the three objectives needed in 
order to make changes.  The behavior objective was for students between the ages of 17 
and 20 years on the Hattiesburg Campus of USM to accept the HPV vaccine.  The 
knowledge objective was to increase students’ awareness of HPV and the HPV vaccine.  
The belief objective was that students would understand that HPV causes cancer in males 
and females and the HPV vaccine will diminish chances of getting HPV-related cancer.  
The goals of this social marketing evidence-based project were to (a) provide education 
about the HPV vaccine and (b) increase the HPV vaccination rates by 20% on the 
Hattiesburg Campus of USM.  
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 Step 5.  Identifying barriers, benefits, competition, and influential others were 
crucial for the success of the capstone project.  The needs assessment revealed that the 
providers offer the HPV vaccine about 10% of the time.  Information about evidence-
based practice was provided to the healthcare providers in an effort to change providers’ 
attitude regarding offering the HPV vaccine to patients.  A change in providers’ 
recommendations could ultimately impact healthcare outcomes. 
 Step 6.  A position statement was important to the success of the social marketing 
project.  The position statement included the audience’s desired behavior, barriers, and 
benefits of the behavioral change.  The position of this capstone project was that the 
students would see that taking the HPV vaccine is safe and effective and will diminish 
their chances of developing HPV-related cancer and genital warts.  Subsequently, there 
will be an increase in the number of students obtaining the HPV vaccine which, in turn, 
will decrease the number of HPV-related cancers, decrease the number of genital warts, 
and result in a decrease in healthcare costs.  
 Step 7.  According to Lee and Kotler (2011), the 4 Ps (product, price, place, and 
promotional strategies) are important for developing a successful marketing project (see 
Appendix A).  The product should identify the main benefit of the target audience, the 
Gardasil® vaccine, which is documented to cause a decrease in HPV-related cancers and 
genital warts.  Strategies to sponsor the capstone project were educational sessions and a 
social marketing campaign.  The cost benefit was useful in building a social marketing 
plan.  The HPV vaccine decreases HPV healthcare costs due to the need for less cancer 
intervention, fewer colposcopies, and fewer genital wart treatments.  Most private 
insurance companies pay for the HPV vaccine in full.  The uninsured or underinsured 
patient was offered access to the patient assistance program through MerckTM.  The 
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setting for implementation of the social marketing project was the Hattiesburg Campus of 
USM.  The educational sessions were held in student housing units (e.g., dormitories and 
sorority houses), and HPV vaccines were offered at the USM Health Clinic.  The 
promotional strategy was the end product of the social marketing project.  A campaign 
theme was used to help promote the message to the target audience (students).  The 
theme for this social marketing project was H.P.V. (Help Prevent the Virus) to promote a 
strong positive message regarding HPV.  The slogan was included on the brochures and 
emails.           
 Step 8.  The evaluation of the social marketing project allows for the opportunity to 
measure the success of the project.  This project’s aim was to increase HPV vaccination 
rates, thus improving healthcare outcomes by decreasing HPV-related cancers, 
decreasing the number of genital warts, and reducing healthcare costs.  Additionally, the 
evaluation of this project provided information to determine if education and researcher 
recommendations play a role in increasing HPV vaccination rates.    
 Step 9.  The established budget to support this social marketing project included the 
product (project), price, place, and promotional strategies.  The budget for the project 
included printing the brochures.  
 Step 10.  The last step of the social marketing project was the implementation plan, 
which was “the process that turns marketing strategies and plans into marketing actions 
in order to accomplish strategic marketing objectives” (Lee & Kotler, 2011, p. 437).  
With a detailed account of the social marketing project, the implementation plan 
specified the what, when, and how much.  
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Pender’s Health Promotion Model 
Although social marketing strategies were utilized to promote a change in 
behavior with this capstone project, Pender’s Health Promotion Model (HPM) also 
strongly supports the initiative of changing behavior to encourage health promotion and 
disease prevention.  Pender developed the HPM, which is an holistic predictive model of 
health-promoting behavior for use in research and practice (Pender, Murdaugh, & 
Parsons, 2006).  Pender’s HPM supports the efforts of this capstone project of taking a 
proactive stance toward health promotion and disease prevention with the conviction that 
it is much better to experience healthy living and prevent disease than to let disease 
happen when it is avoidable and then try to cope with it (Pender et al., 2006).  According 
to Pender et al. (2006), health promotion and disease prevention should be the primary 
focus in health care.  When health promotion and prevention fail to prevent problems, 
then care of illness becomes the next priority.  
 The HPM is grounded in concepts found in Bandura’s social learning theory and 
Fishbein’s theory of reasoned action (Pender et al., 2006).  The same assumptions of the 
HPM were used with the capstone project which reflect nursing and behavioral science 
perspectives:  
1. Persons will seek to create conditions of living through which they can 
express their distinctive human potential. 
2. Persons will be presented with opportunity to self reflect, including 
assessment of their own proficiencies. 
3. Persons will value growth in ways seen as positive and achieve a particular 
balance between change and stability. 
4. Persons will seek to vigorously govern their own behavior. 
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5. Persons will understand that their thoughts and cultural complexity interacts 
with the environment, both gradually transforming the environment and being 
transformed over time. 
6. Healthcare professionals will ascertain a part of the relational environment, 
which influences persons throughout theory lifespan. 
7. Persons will appreciate how critical it is for the person and environmental 
characteristics to match their behavioral change (Pender, Murdaugh, & 
Parsons, 2002).  
 Pender’s HPM is grounded on three categories that can be applied to this project.  
The first category is based on individual characteristics and experiences suggesting that 
past behavior has a direct effect on current health-promoting behavior.  The second 
category focuses on being informed and changing behaviors accordingly.  The variable 
for behavioral-specific knowledge and effect are significant to motivate change.  Nursing 
actions can be used to modify or cause change in behavior. Understanding benefits and 
barriers of action are the behavior-specific cognitions and effect identified in Pender’s 
HPM (Pender et al., 2006).  Third, there must be a plan of action in order to change a 
behavior.  There must be a commitment to a plan of action, even if obstacles occur, in 
order for a behavior to change (Pender et al., 2006).  The end result of health-promoting 
behaviors should improve health.   
 The metaparadigm used by Pender et al. in the HPM is person, environment, 
health, and nursing.  The person is the center of this model.  The HPM considers that 
each person has characteristics and experiences that affect their behavior.  The model 
insinuates that behaviors are learned.  Family and community influence their learned 
behaviors.  A person’s environment, whether it is physical, interpersonal, or economical, 
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will have a direct influence on his or her behavior.  Pender et al. stated health is 
important and is determined by how the person defines it.  The nursing function is to 
raise awareness related to health-promoting behaviors, promote self-efficacy, enhance the 
benefits of change, control the environment to allow for behavior change, and manage the 
barriers to change (Pender et al., 2006). 
 Pender’s (Pender et al., 2006) model was used to assess the students’ knowledge 
of the HPV and identify barriers to health promotion.  Interventions in the HPM focus on 
raising consciousness related to health-promoting behaviors, promoting self-efficacy, 
enhancing the benefits of change, controlling the environment to support change, and 
managing the barriers to change (Pender et al., 2006).  
Doctor of Nursing Practice Essentials 
 The American Association of Colleges of Nursing’s (AACN, 2006) Doctor of 
Nursing Practice (DNP) Essentials was used to support the framework of this capstone 
project.  Implementation of this capstone project met the DNP Essentials of Doctoral 
Education for Advanced Nursing Practice through small group educational sessions, 
evaluation of the sessions, and offering a venue to change the behavior (see Appendix B).  
The capstone project was based on evidence-based research using organizational and 
system leadership to cause behavioral change to improve healthcare, analytical methods 
for evidence-based practice, information/systems technology for improvement of 
healthcare, healthcare policy as an advocacy, collaboration for improved population 
outcomes, clinical prevention using a specific population to improve health, and 
advanced nursing practice (AACN, 2006).   
This capstone project served as a vehicle for the capstone manager to educate and 
change behaviors in students between the ages of 18 and 20 years on the Hattiesburg 
20 
 
 
 
Campus of USM.  Small group educational sessions increased knowledge and behavioral 
outcomes of the students who participated in the program.  The capstone manager served 
as the leader to engage and educate stakeholders to promote a positive outcome. 
Objectives 
This capstone project consisted of three objectives (behavior, knowledge, and 
belief) used to promote change (see Table 1).  The goal of this capstone project using 
social marketing strategies was to increase knowledge regarding HPV and HPV-related 
cancers and incorporating provider recommendations to increase the number of students 
between the ages of 18 and 20 years who received the HPV vaccine on the Hattiesburg 
Campus of USM. 
Table 1 
 
Objectives Relating to Target Audience Using Social Marketing Strategies 
 
 
Objective   Target audience 
 
 
Behavior Students ages 18 to 20 will attend the education session on HPV and 
receive the HPV vaccine. 
                                               
Knowledge Increase awareness of HPV and HPV-related cancers using social                                                
marketing strategies by providing education sessions and using pretests 
and posttests to evaluate. 
 
Belief Students will accept that the HPV vaccine can improve healthcare                                        
outcomes.  
 
Goals   Increase HPV vaccination rates by increasing awareness of HPV  
                                  and HPV-related cancers. 
 
Objective  Increase the HPV vaccination rates among students between the  
   ages of 18 and 20 years on the Hattiesburg Campus of USM. 
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CHAPTER II 
METHODOLOGY 
The purpose of this capstone project was to promote behavioral changes in 
students on the Hattiesburg Campus of USM by using social marketing strategies.  
Education and provider recommendations for the human papillomavirus (HPV) vaccine 
for students are critical if the vaccine rates are to increase.  The capstone manager 
implemented small group education sessions in two different student housing units for 
students between the ages of 18 and 20 years, including males and females, and provided 
a venue for students to receive the HPV vaccine.  The purpose of the small group 
educational sessions was to increase knowledge and promote health by informing the 
group about HPV, HPV-related cancers, and the HPV vaccine.  Social marketing and 
Pender Health Promotion Model (HPM) guided the project.  Following the educational 
sessions, the capstone manager offered H.P.V. (Help Prevent the Virus) month in order to 
achieve positive behavioral changes.  At the completion of the project, data were used to 
help determine if the education sessions and the use of social marketing strategies had a 
positive impact in the number of vaccinations given at the USM Health Clinic.  Data 
collected were reviewed and coded for entry into SPSS. 
Setting 
 The setting for this capstone project was USM Hattiesburg Campus student housing 
units and the USM Health Clinic.  The capstone project intervention consisted of three 
educational sessions and the H.P.V. month.  Two educational sessions were held in the 
common area at Hillcrest Dormitory, which houses males and females, and one session 
was held in the chapter room at the Kappa Delta sorority house.  The HPV vaccines were 
available at the USM Health Clinic. 
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Population 
The population for the capstone project was a random sample of students, males 
and females, between the ages of 18 and 20 years on the USM Hattiesburg Campus.  The 
HPV vaccine is recommended for both males and females regardless of their sexual 
orientation (CDC, 2012a).  Although the HPV vaccine is recommended for both males 
and females at 11 and 12 years of age, catch-up vaccination is recommended between the 
ages of 13 and 26 years for those that did not get the vaccines or did not get all of the 
doses at the earlier age.   
Data Collection Procedure 
Participants were recruited for the capstone project after obtaining approval from 
the Institutional Review Board (IRB) at USM, the USM Health Clinic, and Residential 
Housing (see Appendices C, D, E, and F, respectively).  Participants were recruited 
through the residential assistant (RA).  The project manager contacted the RA and 
requested permission and dates to present the educational session on HPV to students 
between the ages of 18 and 20 years.  The RA sent a mass email inviting students to 
attend the education session.  Participation was on a voluntary basis.  
Before each education session, the project manager gave an introductory oral 
presentation (see Appendix G) explaining the purpose of the session, that participation 
was voluntary, and how confidentiality would be maintained for research purposes.  After 
the introductory oral presentation, informed consent (see Appendix H) was obtained from 
each participant.  Once informed consent was obtained, each participant completed a 
demographic survey (see Appendix I) and completed a pretest (see Appendix J) for the 
purpose of obtaining baseline knowledge regarding HPV.  The demographic survey 
collected information regarding age, race, gender, insurance, and if the participant ever 
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had sex.  The pretest assessed participants’ knowledge of HPV.  The completion of the 
pretest took approximately 10 minutes and was collected from each participant by the 
project manager, placed in a labeled folder, and placed in a sealed manila envelope to 
maintain confidentiality.  
 The educational session lasting approximately 20 minutes was facilitated by the 
project manager.  Focus group education is a helpful tool to collect data for 
understanding the opinions of individuals, implementing change, and gaining valuable 
information of a target group (McLafferty, 2004).  According to Rodriguez (2013), 
educating patients, parents, and providers about HPV and the HPV vaccine is essential in 
order to successfully increase vaccination rates.  After the educational session, the 
posttest (see Appendix J) was given to assess knowledge.  The completion of the posttest 
took approximately 10 minutes and was collected from each participant by the project 
manager and placed in a labeled folder, which was placed in a sealed manila envelope to 
maintain confidentiality.  The project manager allowed approximately 10 minutes for the 
question-and-answer period among the participants.  The first education session was held 
on June 26, 2014, at a campus dormitory with 12 students in attendance.  Seven students 
attended the second education session held on June 30, 2014, at a sorority house. The 
third education session was held on June 30, 2014, at the same dormitory as the first 
session, and there were 10 students in attendance.  
The pretest and posttest were exactly alike and composed of 15 yes or no 
questions.  An expert panel reviewed and answered the questions on the pretest/posttest 
for clarity and readability.  The expert panel consisted of the clinical director, a nurse, 
and a professor.  Virginia Crawford, MD, is the medical director at the USM Health 
Clinic with more than 20 years of experience in student health.  Cindy Heldt is a 
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registered nurse at the USM Health Clinic with > 15 years of experience in student 
health.  Melanie Gilmore, FNP and assistant professor with the USM College of Nursing, 
practices in public health.  
The month of July was dedicated as H.P.V. month for the students to come to the 
USM Health Clinic to receive the HPV vaccine.  At the beginning of July, the RA sent a 
mass email to all student residents reminding them that the HPV vaccine was available in 
the USM Health Clinic.  Once at the clinic, the participants had to sign a consent form 
(see Appendix K) giving the project manager permission to use information obtained 
from HPV form.  The HPV form was completely anonymous, and there were no 
identifying data on the form.  The HPV form collected information regarding the 
participants’ age, which dose of the HPV vaccine was to be given on the day of service, 
and where the participant heard about the HPV/vaccine (see Appendix L).  After 
completion of the form, the form was placed in a folder labeled as “HPV Forms” which 
was kept in the medication supply cabinet in the injection room.  Confidentiality was 
maintained due to no one except the nurse giving the injection had access to the injection 
room.  On July 31, 2014, the capstone manager collected the HPV form folder.  
Design 
The evaluation of the educational session component of the capstone project on 
HPV for students between the ages of 18 and 20 years on the Hattiesburg Campus of 
USM used a pretest and posttest design.  A pretest and posttest design was used to 
evaluate knowledge attainment following the evidence-based HPV educational program.  
Formative process measures included an oral presentation to inform participants of the 
program, inform consent to participate, and completion of a demographic survey.  
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Demographic Data 
The demographic survey asked participants to give their age, gender, and race. 
Further, the survey asked the participant to choose a category regarding insurance status 
and sex.  
Pretest/Posttest 
The educational session was evaluated by assessing students’ knowledge of HPV 
through a pretest/posttest design that measured knowledge of HPV, epidemiology, and 
prevention of the disease.  The pretest and posttest consisted of 15 yes or no questions.  
Program Evaluation 
 H.P.V. (Help Prevent the Virus) month was designed to evaluate the evidence-
based education intervention.  The month following the intervention was set aside for the 
HPV participants to come to the USM Health Clinic to receive the HPV vaccine.  The 
participants gave the date, their age, and chose from categories regarding dose of vaccine, 
and how they heard about HPV/vaccine on the HPV form. 
Ethical and Human Subject Issues 
The University of Southern Mississippi’s Institutional Review Board (IRB) 
approved the capstone project that informs students about HPV, the risks of HPV-related 
cancers, and the prevention of HPV by the use of social marketing strategies (see 
Appendix C).  The risk to participants was minimal in this capstone project.  The 
participants were volunteers and could withdraw at any time without penalty.  Placing the 
education session data collection forms in sealed envelopes protected the participants’ 
confidentiality and anonymity.  Access to this collected data was available to the project 
leader only.  The HPV vaccine data collection forms kept in a labeled folder in the 
medication supply cabinet protected the participants’ confidentiality and anonymity.  
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Access to this collected data was available to the nurse that gave the vaccine and project 
leader.   
Data Analysis 
The data from this capstone project included demographic data as well as the 
pretest/posttest that were analyzed using a paired t test to assess the effectiveness of the 
intervention on HPV knowledge.  The evaluation of the H.P.V. month was analyzed 
using descriptive statistics designed to measure the number of vaccines given.  
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CHAPTER III 
RESULTS 
 The aim for the project was to determine if educating students about the human 
papallomavirus (HPV) and HPV-related cancers would help change behavior with regard 
to obtaining the HPV vaccine.  The educational sessions were held in student housing 
units.  Two were sessions held at one of the campus dormitories, and one session was 
held at one of  the sorority houses.  The group email was critical to the success of the 
social marketing educational event, and the educational sessions were well received as 
evidenced by the number of participants.  H.P.V. (Help Prevent the Virus) brochures 
were given out after the educational session to help reiterate the facts about HPV and the 
vaccine (see Appendix M).  Data were collected from June 2014 through July 2014.  A 
demographic survey was used to determine age, sex, gender, and if the participant had 
ever had sex.  A pretest was administered prior to the educational session to record 
participants’ knowledge about HPV, and a posttest was administered to evaluate 
knowledge.following the session.  Participants (N = 25) in the study were students 
between the ages of 18 and 20 years attending classes on the Hattiesburg Campus of 
USM.  A total of 29 students signed up to participate in the study, but only 25 
participants met the age requirements.  Graphs and tables are included to present the 
results of this project. 
Demoographics of the Sample 
 Analysis of the demographic information from the participants indicated 60% of the 
participants were African American and 36% were Caucasian.  The smallest portion was 
Asian, representing 4%.  There were 14 female and 11 male participants between the ages 
28 
 
 
 
of 18 and 20 years.  Most particpants (76%) reported having private insurance, and 84% 
reported they had had sexual encounters (see Table 2). 
Table 2 
 
Frequencies and Percentages of Demographic Variables 
 
 
Variable                  f        % 
 
 
Age (years) 
     18        3             12.0 
     19      12              48.0 
     20      10                 40.0 
     Total                25               100.0 
 
Gender 
     Male     11      44.0 
     Female     14                 56.0 
     Total     25               100.0 
 
Race 
     African American    15      60.0 
     Caucasian       9      36.0 
     Asian       1        4.0 
     Total     25    100.0 
 
Insurance 
     Private     19      76.0 
     No        3      12.0 
     Not Sure       3      12.0 
     Total     25    100.0 
 
Ever had sex 
     Yes      21      84.0 
     No        4      16.0 
     Total     25    100.0 
 
 
The pretest data were used to assess participants’ knowledge of HPV (see Table 
3).  Prior to the educational sessions, the majority of the participants reported they had 
never heard of HPV or did not know what it was.  Most participants understood that men 
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and women could get HPV and not be aware of the infection.  Eighty-four percent of the 
participants knew that condoms did not always protect against HPV.  Participants (n = 
15) knew that HPV could not only be contracted by sexual intercourse but by oral sex (n 
= 22) as well and may not be cured with antibiotics (n = 18).  The majority (56%) of the 
participants reported never being offered the HPV vaccine but would take the HPV 
vaccine if their provider recommended it.  The data regarding previous immunization 
with HPV vaccine were analyzed using descriptive statistics.  Four of the participants had 
previously taken one dose of the vaccine, and 3 participants had received all 3 doses of 
the vaccine. 
Table 3 
 
Frequencies and Percentages of Pretest Variables 
 
 
Variable                  f         % 
 
 
Pr1 I have heard of HPV. 
           Yes     10         40.0 
         No      15         60.0  
            Total     25       100.0 
 
Pr2  I have heard of HPV but do not really know what it means. 
    Yes     14         56.0 
     No     11         44.0 
     Total     25       100.0 
 
Pr3  Only women can get HPV. 
     Yes       1         4.0 
           *No     23                  92.0 
     Left blank      1         4.0 
     Total     25          100.0 
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Table 3 (continued). 
 
 
Variable                  f         % 
 
 
Pr4  Men can get HPV. 
          *Yes     21       84.0 
     No       4       16.0 
     Total     25     100.0 
 
Pr5  Condoms always protect you from HPV. 
    Yes     3                  12.0 
          *No     21       84.0 
     Left Blank    1         4.0 
     Total     25     100.0 
 
Pr6  Females may be infected with HPV and not know it. 
         *Yes     23       92.0 
     No     2         8.0 
     Total     25     100.0 
 
Pr7  Males may be infected with HPV and not know it. 
          *Yes     23       92.0 
     No     2         8.0 
     Total     25     100.0 
 
Pr8  A person can only get HPV by having sexual intercourse. 
     Yes     10       40.0 
          *No     15       60.0 
     Total     25     100.0 
 
Pr9  HPV infection is rare among men. 
     Yes     6       24.0 
          *No     19       76.0 
     Total     25     100.0 
 
Pr10  If you get HPV, you will have it for life. 
          *Yes     13       52.0 
     No     12       48.0 
     Total     25     100.0 
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Table 3 (continued). 
 
 
Variable                  f         % 
 
 
Pr11  HPV may be spread from person to person through oral sex. 
          *Yes     22       88.0 
     No     3       12.0 
    Total     25     100.0 
 
Pr12  HPV can be cured with antibiotics. 
Yes     6       24.0  
      *No     18       72.0 
     Left Blank    1         4.0 
     Total     25     100.0 
 
Pr13  HPV vaccine has never been offered to me. 
     Yes     10       40.0 
     No     14.0       56.0 
     Left Blank    1         4.0 
     Total     25     100.0 
 
Pr15  If your healthcare provider recommends the HPV vaccine, will you take it? 
     Yes     21       84.0 
     No     2         8.0 
     Left Blank    2         8.0 
    Total     25     100.0 
 
 
Note.  Asterisk indicates correct answers to knowledge questions. 
 
The posttest data in Table 4 was used to evaluate any improvement in 
participants’ knowledge of HPV.  After the educational session, the number of 
participants knowing that men and women could get HPV and not be aware of the 
infection increased by 8%.  Only one person still thought that condoms would always 
protect from HPV.  The data revealed a 12% increase in participants’ knowledge that 
HPV can be contracted by oral sex.  More than one half of the participants said the HPV 
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vaccine had never been offered, but 100% reported they would take the HPV vaccine if 
their provider recommended it.     
Table 4 
 
Frequencies and Percentages of Posttest Variables 
 
 
Variable                  f         % 
 
 
Po1  I have heard of HPV. 
    Yes       7        28.0 
     No      18        72.0 
     Total     25      100.0 
 
Po2  I have heard of HPV but do not really know what it means. 
     Yes       1          4.0 
     No     24        96.0 
     Total     25      100.0 
 
Po3  Only women can get HPV. 
     Yes       1          4.0 
          *No     24        96.0 
     Total     25      100.0 
 
Po4  Men can get HPV. 
          *Yes     25      100.0 
      No       0          0.0 
     Total     25      100.0 
 
Po5  Condoms always protect you from HPV. 
    Yes       1          4.0 
           *No     24        96.0 
     Left Blank      1          4.0 
     Total     25      100.0 
 
Po6  Females may be infected with HPV and not know it. 
         *Yes     24        96.0 
     No         1          4.0 
Total                25      100.0 
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Table 4 (continued). 
 
 
Variable                  f         % 
 
 
Po7  Males may be infected with HPV and not know it. 
          *Yes     25      100.0 
     No       0          0.0 
     Total     25      100.0 
 
Po8  A person can only get HPV by having sexual intercourse. 
     Yes       9        36.0 
          *No     16        64.0 
     Total     25      100.0 
 
Po9  HPV infection is rare among men. 
     Yes       2          8.0 
          *No     23        92.0 
     Total     25      100.0 
 
Po10  If you get HPV, you will have it for life. 
         *Yes     20        80.0 
     No       5        20.0 
     Total     25      100.0 
 
Po11  HPV may be spread from person to person through oral sex. 
         *Yes     25      100.0 
     No       0          0.0 
     Total     25      100.0 
 
Po12 HPV can be cured with antibiotics. 
 Yes       1          4.0 
          *No     23        92.0 
 Left blank      1          4.0 
 Total     25      100.0 
 
Po13 HPV vaccine has never been offered to me. 
 Yes       7        28.0 
 No     18        72.0 
 Total     25      100.0 
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Table 4 (continued). 
 
 
Variable                  f         % 
 
 
 
Po15 If your healthcare provider recommends the HPV vaccine, will you take it? 
     Yes     25      100.0 
     No       0          0.0 
    Total     25      100.0 
 
 
Note.  Asterisk indicates correct answers to knowledge questions. 
 
Evaluation Plan 
 The goal of the intervention was to educate participants about HPV and HPV-
related cancer using a social marketing framework.  The pretest instrument was 
administered to identify demographics, behaviors, and understanding before the 
educational session.  The posttest was used to evaluate changes in knowledge level 
following the educational session.  The H.P.V. month was scheduled to allow participants 
to voluntarily come to the USM Health Clinic to request the HPV vaccine.  The total 
number of HPV vaccines given in the month of July at the USM Health Clinic was 
compared to the total number of HPV vaccines administered the previous 6 months 
(January-June) at the clinic.  An increase in the number of HPV vaccines administered 
was the desired outcome.  
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CHAPTER IV 
DISCUSSION 
 According to researchers, healthcare professionals’ failure to recommend the 
HPV vaccine is among the leading barriers concerning low HPV vaccination rates 
(Ylitalo et al., 2013).  The purpose of this study was to increase knowledge of the human 
papillomavirus (HPV) and HPV-related cancers and, in turn, increasing the number of 
HPV vaccines given on the Hattiesburg Campus of USM.  The educational session was 
an informal and nonthreatening way to inform the group about HPV.  A total of three 
educational sessions were offered.  The H.P.V. (Help Prevent the Virus) brochures were 
provided to reiterate facts about HPV and HPV-related cancers.  Most participants 
participated in the question-and-answer period at the end of the session. The participants 
had one month to request the vaccine.  
Interpretation of Results 
The findings of the capstone project indicated that the participants benefited 
from participating in the educational sessions.  The evaluation of data showed positive 
knowledge changes in each area of the posttest.  The posttest was higher than the  
pretest (see Table 5).  This increase was seen in the analysis of the data generated  
by using a paired t test, t(24) = 3.00, p =.006.  The difference was statistically  
significant.  
  
36 
 
 
 
Table 5 
 
Means and Standard Deviations on the Pretest/Posttest 
 
 
Test        M       SD 
 
 
Pretest      7.92     1.85 
 
Posttest     9.20     1.00 
 
 
 
Data analysis after the intervention revealed increasing knowledge about HPV, 
and recommending the HPV vaccine has the potential to change behavior regarding HPV.  
At the end of the H.P.V. month, there was an increase in the number of students who 
received the vaccine at the USM Health Clinic.  Data collected for H.P.V. month were 
analyzed using descriptive statistics.  A total of 9 students came to the clinic and 
requested the HPV vaccine, but only 8 participants met the requirements (see Figure 1).   
 
 
Figure 1. Total number of vaccines from January-June 2014 compared to July 2014 
(H.P.V. Month) at the USM Health Clinic.  
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Participants (n = 8) receiving the HPV vaccine were students from the USM 
Hattiesburg Campus between the ages of 18 and 20 years.  The 8 participants who 
participated in the study reported hearing about HPV in an educational session.  The one 
who was omitted reported hearing about HPV from a group email.  Seven participants 
initiated the vaccine, and one participant took the second dose.  One 18-year-old, four 19-
year-olds, and three 20-year-olds participated in H.P.V. month. 
Limitations 
 Limitations identified during the evaluation of this project were time constraints 
and a small sample size that used self-reported data.  The project manager had a narrow 
window of time to set up educational sessions in order to have an H.P.V. month.  The 
educational sessions were held in the middle of the summer when most students were not 
on campus which limited access to the population sample and, therefore, may not be  
representative of the University’s population.    
Implications for Practice, Research, and Education 
 HPV is the most common STD in the United States.  According to Fontenot et al. 
(2014), 50% of new HPV infections are individuals between the ages of 15 and 24 years.  
Research states that the primary age for the HPV vaccine is between the ages of 9 and 11 
years and prior to the first sexual encounter.  However, there is a secondary focus to catch 
up  vaccines through the age of 26 years.  Research supports vaccinating against HPV 
even if already sexually active to prevent new infections.  Many researchers suggest that 
vaccination rates are low due to lack of provider recommendations.  This project manager 
postulated that when the vaccine is understood and recommended, it is more likely to be 
accepted.  Findings from this project revealed 100%  of the participants would take the 
HPV vaccine if recommended by their healthcare provider.  Implications for future 
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practice should include  providers capitalizing on each patient encounter to educate 
students about HPV and recommend the HPV vaccine.  Additionally, the project manager 
would continue to offer educational sessions on HPV and HPV-related cancers. 
Conclusions 
 Social marketing and Pender’s HPM are valid frameworks for use in health care 
to help change behaviors of individuals.  The social marketing strategies used to increase 
HPV vaccination rates on the Hattiesburg Campus of USM were effective and could be 
replicated for other college campuses.  Increasing HPV vaccination rates will improve 
healthcare outcomes; therefore, it is incumbent upon healthcare providers to educate and 
recommend the HPV vaccine.  Strategies to increase HPV vaccination rates include (a) 
educating healthcare professionals and the general public about the importance of 
vaccinating adolescent males and females and (b) ensuring that underserved populations 
are informed about and given access to the vaccine (Moon, 2013).  DNP graduates are in 
a  unique position to be influential in implementing programs that educate about HPV 
and HPV-related cancer to increase vaccination rates.     
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APPENDIX A 
 
FRAMEWORK FOR SOCIAL MARKETING: THE FOUR Ps 
PRODUCT > PRICE > PLACE > PROMOTION 
 
 
 
 
 
 
 
 
 
 
 
  
Product
• Gardasil® vaccine, which is documented to cause a decrease in 
the HPV related cancers and genital warts.
Price
• The HPV vaccine will decrease HPV healthcare costs due to the 
need for less cancer intervention, fewer colposcopies, and fewer 
genital wart treatment
Place
• The setting for implementation of the social marketing project will 
be on the Hattiesburg Campus of USM.  The educational sessions 
will be held in student housing (dorms, sorority houses, fraternity 
houses) and the HPV vaccines will be offered at the USM health 
clinic
Promotion
• 1) Educational program 2) Campaign material for HPV called 
H.P.V. (Help Prevent the Virus) 3)Dedicated HPV month
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APPENDIX B 
 
DNP ESSENTIALS AND CLINICAL IMPLICATIONS FOR THIS PROJECT 
 
 
DNP Essentials 
 
DNP Capstone Clinical Implications 
Essential I:  
Scientific Underpinning for  
Practice 
With the integration of social marketing 
strategies and Pender’s HPM, this project will 
be used to increase knowledge about HPV and 
HPV-related cancers. Using these two 
frameworks will promote positive changes and 
an understanding of how Gardasil® is used to 
prevent HPV.  The evidence-based research 
will allow the nurse practitioner to improve  
the overall health of the target population. 
 
Essential II:  
Organizational and Systems 
Leadership for Quality  
Improvement and Systems  
Thinking 
 
The project will offer new approaches for 
meeting healthcare needs of the target 
population by using social marketing strategies 
offering HPV education, thus raising 
awareness to improve the health of the target 
population.  Increasing the number of HPV 
vaccines given on USM Hattiesburg Campus 
will improve overall health of the campus. 
 
Essential III:  
Clinical Scholarship and Analytical 
Methods for Evidence-Based  
Practice 
 
This project will disseminate findings from 
evidence-based research to improve HPV 
outcomes of students between the ages of 18 
and 20 years on the USM Hattiesburg Campus. 
  
Essential IV:  
Information Systems/Technology 
and Patient care Technology 
 
The capstone project manager utilized 
information systems and technology to review 
literature through data searches and designed 
and implemented a program using social 
marketing strategies to improve HPV 
outcomes.  
 
Essential V:  
Healthcare Policy  
for Advocacy in Health Care 
The Capstone project manager demonstrated 
leadership skills in developing and 
implementing an intervention to facilitate 
change for a target population and 
incorporating key stakeholders.  
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Essential VI:  
Interprofessional Collaboration for 
Improving Patient and Population 
Health Outcomes 
 
For the project manager to function as a 
change agent, key stakeholders were identified 
and collaborated with within the organization 
to help increase the number of HPV vaccines 
received on the USM Hattiesburg Campus. 
 
Essential VII:  
Clinical Prevention and Population 
Health for Improving the Nation’s 
Health 
 
The project allowed the project manager to 
promote health and improve outcomes by 
offering education sessions about HPV and 
HPV-related cancers and a venue to receive the 
vaccine to prevent HPV.  
 
Essential VIII:  
Advanced Nursing Practice 
Utilized advanced nursing practice to 
implement education and prevention strategies 
for HPV and HPV-related cancers for students 
between the ages of 18 and 20 years on the 
USM Hattiesburg Campus.  
 
Source: American Association of Colleges of Nursing, 2006 
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APPENDIX C 
IRB APPROVAL LETTER 
 
 
INSTITUTIONAL REVIEW BOARD 
118 College Drive #5147 | Hattiesburg, MS 39406-0001  Phone: 601.266.5997 | 
Fax: 601.266.4377 | www.usm.edu/research/institutional-review-board 
NOTICE OF COMMITTEE ACTION 
The project has been reviewed by The University of Southern 
Mississippi Institutional Review Board in accordance with 
Federal Drug Administration regulations (21 CFR 26, 111), 
Department of Health and Human Services (45 CFR Part 46), 
and university guidelines to ensure adherence to the following 
criteria:   
The risks to subjects are minimized.  
The risks to subjects are reasonable in relation to the anticipated 
benefits.  
The selection of subjects is equitable.  
Informed consent is adequate and appropriately documented.  
Where appropriate, the research plan makes adequate 
provisions for monitoring the data   collected to ensure the safety 
of the subjects.  
Where appropriate, there are adequate provisions to protect the 
privacy of subjects and to   maintain the confidentiality of all 
data.  
Appropriate additional safeguards have been included to protect 
vulnerable subjects.  
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Any unanticipated, serious, or continuing problems encountered 
regarding risks to subjects must   be reported immediately, but 
not later than 10 days following the event. This should be 
reported   to the IRB 
Office  via  the  “Adverse  Effect  Report  Form”.  
If approved, the maximum period of approval is limited to twelve 
months.   Projects that exceed this period must submit an 
application for renewal or continuation.  
PROTOCOL NUMBER: 14050601   
PROJECT TITLE: Increasing HPV Vaccination Rates  
Using Social Marketing Strategies  
PROJECT TYPE: New Project   
RESEARCHER(S): Sharon Catledge   
COLLEGE/DIVISION: College of Nursing   
DEPARTMENT: Systems Leadership 
FUNDING AGENCY/SPONSOR: N/A   
IRB COMMITTEE ACTION: Expedited Review Approval   
PERIOD OF APPROVAL: 05/06/2014 to 05/05/2015    
 
Lawrence A. Hosman, Ph.D.  
Institutional Review Board  
 
  
44 
 
 
 
APPENDIX D 
 
THE UNIVERSITY OF SOUTHERN MISSISSIPPI CLINIC PERMISSION LETTER 
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APPENDIX E 
 
INFORMATIONAL LETTER 
 
 
TO:    Justin Long, Associate Director of Residence Living 
 
FROM:   Sharon Catledge, MSN, FNP-C 
 
RE:    Educational Program/Health & Wellness 
 
 
Mr. Long, I have developed an educational program on Human papillomavirus (HPV), 
and I would like to present this program to students between the ages of 18 and 20 years 
living on the Hattiesburg Campus of The University of Southern Mississippi.  The 
program will highlight HPV, HPV-related cancers, and HPV prevention.  
 
Please share this information with your RAs.  They can contact me at 601-266-5390 or 
sharon.catledge@usm.edu to set up a time for the program. 
 
 
Respectfully submitted, 
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APPENDIX F 
 
RESIDENCE LIFE PERMISSION LETTER 
 
 
DEPARTMENT OF RESIDENCE LIFE 118 College Drive #5064 | Hattiesburg, MS 39406-
0001 Phone: 601.266.4783 | Fax: 601.266.4891 | reslife@usm.edu | 
www.usm.edu/residence-life 
April 24, 2014 To Whom It May Concern: 
I have met with Sharon Catledge regarding her capstone project and a way to integrate 
it within our residence halls. We have a passion for educational programming in our 
department and are happy to agree to allow her to present to our residential students. 
If you have any questions, please contact me at 601.266.4792 or via email at 
Justin.Long@usm.edu. 
Sincerely, 
Justin Long Associate Director 
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APPENDIX G 
ORAL PRESENTATION  
Good evening.  I am Sharon Catledge, a certified family nurse practitioner and 
Doctor of Nursing Practice student at The University of Southern Mississippi. According 
to the Centers for Disease Control and Prevention, human papillomavirus is the most 
common sexually-transmitted infection.  Approximately 20 million Americans between 
the ages of 15 and 49 years currently have the human papillomavirus (HPV) with more 
than 6.2 million new HPV infections estimated to occur each year; yet, HPV vaccination 
rates remain relatively low.  
 The goal of this project is to increase the number of students between the ages of 
18 and 20 years receiving the HPV vaccination.  The program will raise awareness of 
HPV and increase knowledge about HPV and HPV-related cancers. 
 You will be administered a pretest to assess your knowledge of HPV and HPV-
related cancers.  After taking the pretest, the test will be returned to the project director 
and placed in a sealed envelope where only the presenter will have access.  The 
educational session will then be presented and will consist of an oral presentation 
designed to enhance knowledge of HPV and HP- related cancers followed by a question-
and-answer session.  At the end of the program, you will be administered a posttest to 
assess your knowledge gained from the program.  The posttest will be returned to the 
project director and placed a sealed envelope where only the presenter will have access. 
The pretest/posttest will be used to collect data, kept with the project director up to 6 
months, and then discarded.  
 The project has been reviewed by the Institutional Review Board, which ensures 
that research projects involving human subjects follow federal regulations.  Participation 
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in this project is completely voluntary, and participants may withdraw from the study at 
any time without penalty or prejudice.  Any questions or concerns about rights as a 
research participant should be directed to the chair of the Institutional Review Board at 
The University of Southern Mississippi 601-266-5997.  Any questions regarding the 
research should be directed to the following faculty: 
Sharon Catledge, MSN, FNP-C   or     Melanie Gilmore, PhD, FNP-C, Project Chair 
The University Of Southern Mississippi      Assistant Professor, School of Nursing 
118 College Drive #5066   118 College Drive #5095 
Hattiesburg, MS 39402   Hattiesburg, MS 39402 
601-266-5390     601-266-6846 
sharon.catledge@usm.edu   melanie.gilmore@usm.edu 
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APPENDIX H 
 
INSTITUTIONAL REVIEW BOARD SHORT FORM CONSENT 
 
 
Today’s date:           
Project Information 
Project Title:       
Principal Investigator:       Phone:       Email:       
College:            Department:       
CONSENT TO PARTICIPATE IN RESEARCH 
   
Participant’s Name:                      
 
Consent is hereby given to participate in this research project. All procedures and/or 
investigations to be followed and their purpose, including any experimental procedures, were 
explained. Information was given about all benefits, risks, inconveniences, or discomforts that 
might be expected. 
 
The opportunity to ask questions regarding the research and procedures was given. Participation 
in the project is completely voluntary, and participants may withdraw at any time without 
penalty, prejudice, or loss of benefits. All personal information is strictly confidential, and no 
names will be disclosed. Any new information that develops during the project will be provided 
if that information may affect the willingness to continue participation in the project. 
 
Questions concerning the research, at any time during or after the project, should be directed to 
the Principal Investigator using the contact information provided above. This project and this 
consent form have been reviewed by the Institutional Review Board, which ensures that 
research projects involving human subjects follow federal regulations. Any questions or 
concerns about rights as a research participant should be directed to the Chair of the 
Institutional Review Board, The University of Southern Mississippi, 118 College Drive #5147, 
Hattiesburg, MS 39406-0001, (601) 266-5997. 
 
                                   
____________________________  ____________________________ 
Research Participant                 Person Explaining the Study                
               
____________________________              ____________________________ 
Date                              Date 
 
 
 
 
  
50 
 
 
 
APPENDIX I 
DEMOGRAPHIC INFORMATION 
Age (years): ____ Gender:  Male___    Female___  Race: __________________ 
Do you have insurance? (Check one) 
 
 ____  Private  ____ Other ____ Not sure      ____ No 
 
Have you had sexual intercourse?    
 ____ Yes          ____ No   
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APPENDIX J 
PRETEST/POSTTEST 
HPV Knowledge: 
1. I have heard of HPV.            YES or NO 
2. I have heard of HPV but do not really know what it means.     YES or NO 
3. Females can get HPV.            YES or NO 
4. Males can get HPV.            YES or NO 
5. Condoms always protect you from HPV.         YES or NO 
6. Females may be infected with HPV and not know it.       YES or NO 
7. Males may be infected with HPV and not know it.       YES or NO 
8. A person can only get HPV by having sexual intercourse.      YES or NO 
9. HPV infection is rare among men.          YES or NO 
10. If you get HPV, you will you have it for life.        YES or NO 
11. HPV may be spread from person-to-person through oral sex.     YES or NO 
12.  HPV can be cured with antibiotics.         YES or NO 
13. HPV vaccine has never been offered to me.          YES or NO 
14. Have you taken the HPV vaccine? 
Only 1 dose            YES or NO 
2 doses              YES or NO 
Received all three doses          YES or NO 
 
15. If your healthcare provider recommends the HPV vaccine, will  
you take it?             YES or NO 
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APPENDIX K 
 
INSTITUTIONAL REVIEW BOARD LONG FORM CONSENT 
 
 
Today’s date:           
Project Information 
Project Title:       
Principal Investigator:       Phone:       Email:       
College:            Department:       
RESEARCH DESCRIPTION 
 
1. Purpose:  
 [Describe purpose of the investigation, why it is being performed and what use may be 
made of the results.]   
2. Description of Study:  
 [Describe the experimental procedure(s), including duration, amount of time required of the 
participants, number of participants, restrictions on normal activities, invasive techniques 
etc.]   
3. Benefits:  
 [Describe any benefits that may occur to the participant or to others as a result of 
participation in the study, including all benefits or payments.]  If the potential for medical 
injury exists, identify treatment procedures or the absence thereof 
4. Risks: 
 [Describe any known physical, psychological, social, or financial research-related risks, 
inconveniences, or side effects (expected and potential) and indicate what measures will be 
taken to minimize them. 
5. Confidentiality: 
 [Describe confidentiality procedures.  Detail the extent, if any, to which confidentiality of 
records identifying the participant will be protected.]   
6. Alternative Procedures:  
 [Describe alternatives to participation that will be presented to participation in the study 
(generally another accepted course of therapy or diagnostic procedure etc.).]  
7. Participant’s Assurance:  
This project has been reviewed by the Institutional Review Board, which ensures that 
research projects involving human subjects follow federal regulations.  
Any questions or concerns about rights as a research participant should be directed to the 
Manager of the IRB at 601-266-5997.Participation in this project is completely voluntary, 
and participants may withdraw from this study at any time without penalty, prejudice, or 
loss of benefits.  
Any questions about the research should be directed to the Principal Investigator using the 
contact information provided in Project Information Section above. 
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CONSENT TO PARTICIPATE IN RESEARCH 
   
Participant’s Name:            
Consent is hereby given to participate in this research project. All procedures and/or 
investigations to be followed and their purpose, including any experimental procedures, were 
explained. Information was given about all benefits, risks, inconveniences, or discomforts that 
might be expected. 
 
The opportunity to ask questions regarding the research and procedures was given. 
Participation in the project is completely voluntary, and participants may withdraw at any 
time without penalty, prejudice, or loss of benefits. All personal information is strictly 
confidential, and no names will be disclosed. Any new information that develops during the 
project will be provided if that information may affect the willingness to continue 
participation in the project. 
 
Questions concerning the research, at any time during or after the project, should be directed to 
the Principal Investigator with the contact information provided above. This project and this 
consent form have been reviewed by the Institutional Review Board, which ensures that research 
projects involving human subjects follow federal regulations. Any questions or concerns about 
rights as a research participant should be directed to the Chair of the Institutional Review Board, 
The University of Southern Mississippi, 118 College Drive #5147, Hattiesburg, MS 39406-0001, 
(601) 266-5997. 
 
Include the following information only if applicable otherwise delete this entire 
paragraph before submitting for IRB approval: The University of Southern Mississippi has 
no mechanism to provide compensation for participants who may incur injuries as a result of 
participation in research projects. However, efforts will be made to make available the facilities and 
professional skills at the University. Participants may incur charges as a result of treatment related to 
research injuries. Information regarding treatment or the absence of treatment has been given.   
 
                                   
____________________________   ____________________________ 
Research Participant      Person Explaining the Study 
 
                               
____________________________   ____________________________ 
Date       Date 
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APPENDIX L 
HUMAN PAPILLOMAVIRUS VACCINATION FORM 
 
Date: ___________         Age: _________  
Which dose of the HPV are you receiving today (circle one):  1     2    3 
Where did you hear about the HPV vaccine? (Check all that apply): 
 _____  Attended an educational session on HPV. 
 _____  Saw an HPV (Help Prevent the Virus) poster. 
 _____  Saw an HPV (Help Prevent the Virus) flier. 
 _____  Other (please specify): ______________________________________________ 
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APPENDIX M 
 
HUMAN PAPILLOMAVIRUS BROCHURE 
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